Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

NCT05227703 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05227703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05227703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2022
Completion date
September 11, 2024
Enrollment
391 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia